Home › Triple-Negative Breast Cancer › Virginia
Triple-Negative Breast Cancer clinical trials in Virginia
29 studies for Triple-Negative Breast Cancer are looking for participants at sites in Virginia.
Cities in Virginia
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- VCU Massey Comprehensive Cancer Center, Richmond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03606967A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Virginia Oncology Associates (VOA) ( Site 8002), Norfolk
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Mary Washington Hospital ( Site 0129), Fredericksburg
- Hematology Oncology Associates of Fredericksburg ( Site 9550), Fredericksburg
- Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020), Midlothian
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06393374Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University of Virginia, Charlottesville
- Inova Fairfax Hospital, Fairfax
- Bon Secours Cancer Institute at St. Francis, Midlothian
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472Study of XB010 in Subjects With Solid Tumors
- Inova Schar Cancer, Fairfax
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06545331Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NEXT Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06799065A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07749586A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07115043The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Bon Secours St. Francis Medical Center, Midlothian
- Local Institution - 0301, Roanoke
- Shenandoah Oncology, P.C., Winchester
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
RecruitingPhase 2
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT04348747A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- NEXT Oncology Virginia, Fairfax
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Virginia Oncology Associates, Norfolk
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 30, 2026 · NCT06926920A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 7, 2026 · NCT06999187A Study of NX-1607 in Adults With Advanced Malignancies
- University of Virginia, Charlottesville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- Next Oncology, Virginia Cancer Specialists, Fairfax
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 26, 2024 · NCT05746897From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.